Already in the 1970s and 80s, CTPS was suggested to be an attractive target in anti-cancer therapy due to its observed increase in activity leading to elevated CTP levels in lymphocytic and non-lymphocytic leukemia, liver as well as renal carcinoma, and in a variety of other cancers [113,114,115]. The gene discussed is CTPS1; the disease is cancer.